Effects of sodium butyrate in animal models of mania and depression: implications as a new mood stabilizer
Abstract
Bipolar disorder is a severe mood disorder with high morbidity and mortality. Despite adequate treatment, patients continue to have recurrent mood episodes, residual symptoms, and functional impairment. Some preclinical studies have shown that histone deacetylase inhibitors may act on depressive-like and manic-like behaviors. Therefore, the aim of the present study was to evaluate the effects of sodium butyrate (SB) on behavioral changes in animal models of depression and mania. The animals were submitted to protocols of chronic mild stress or maternal deprivation for induction of depressive-like behaviors and subjected to amphetamine, or ouabain administration for induction of manic-like behaviors. SB reversed the depressive-like and manic-like behaviors evaluated in the animal models. From these results we can suggest that SB may be a potential mood stabilizer.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Sodium butyrate is capable of reversing behavioral hyperactivity and depressive-like and manic-like behaviors in rats.
“Sodium butyrate has been shown to be capable of reversing behavioral hyperactivity (155) and depressive-like and manic-like behaviors in rats (156).”
From The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication (2020) · cites this paper as [156]
Cites
The tail suspension test: A new method for screening antidepressants in mice
Steru, L., Chermat, R., Thierry, B., & Simon, P. (1985) · Psychopharmacology · doi:10.1007/bf00428203 · Cited by 3,534 · see citing works
Histone acetylation: molecular mnemonics on the chromatin
Gräff, J., & Tsai, L.-H. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3427 · Cited by 680 · see citing works
Role of neurotrophic factors in depression
CASTREN, E., VOIKAR, V, & RANTAMAKI, T. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2006.08.009 · Cited by 667 · see citing works
Kupka, R. W., Altshuler, L. L., Nolen, W. A., Suppes, T., Luckenbaugh, D. A., Leverich, G. S., Frye, M. A., Keck, P. E., McElroy, S. L., Grunze, H., et al. (2007) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00467.x · Cited by 397 · cited 1× · see citing works
“Although the clinical hallmark for the diagnosis of BD is the presence of manic symptoms, depression represents the predominant mood state for treated patients with bipolar I and II disorders (Judd et al., 2003; Kupka et al., 2007).”
BackgroundLong-term symptomatic status of bipolar I vs. bipolar II disorders
Judd, L. L., Schettler, P. J., Akiskal, H. S., Maser, J., Coryell, W., Solomon, D., Endicott, J., & Keller, M. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003341 · Cited by 389 · see citing works
Regulation of Neurogenesis and Gliogenesis by Stress and Antidepressant Treatment
Banasr, M., & Duman, R. (2007) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152707783220929 · Cited by 169 · see citing works
Effects of the histone deacetylase inhibitor sodium butyrate in models of depression and anxiety
Gundersen, B. B., & Blendy, J. A. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.04.008 · Cited by 112 · see citing works
Behavioral and neurochemical effects of sodium butyrate in an animal model of mania
Moretti, M., Valvassori, S. S., Varela, R. B., Ferreira, C. L., Rochi, N., Benedet, J., Scaini, G., Kapczinski, F., Streck, E. L., Zugno, A. I., et al. (2011) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e32834d0f1b · Cited by 84 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
The role of short-chain fatty acids in microbiota–gut–brain communication
Dalile, B., Van Oudenhove, L., Vervliet, B., & Verbeke, K. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0157-3 · Cited by 3,357 · see citing works
The Role of Short-Chain Fatty Acids From Gut Microbiota in Gut-Brain Communication
Silva, Y. P., Bernardi, A., & Frozza, R. L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00025 · Cited by 3,043 · see citing works
“Sodium butyrate has been shown to be capable of reversing behavioral hyperactivity (155) and depressive-like and manic-like behaviors in rats (156).”
BackgroundMinocycline alters behavior, microglia and the gut microbiome in a trait-anxiety-dependent manner
Schmidtner, A. K., Slattery, D. A., Gläsner, J., Hiergeist, A., Gryksa, K., Malik, V. A., Hellmann-Regen, J., Heuser, I., Baghai, T. C., Gessner, A., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0556-9 · Cited by 153 · see citing works
Varela, R. B., Valvassori, S. S., Lopes-Borges, J., Mariot, E., Dal-Pont, G. C., Amboni, R. T., Bianchini, G., & Quevedo, J. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.11.003 · Cited by 115 · see citing works
Wang, P., Zhang, Y., Gong, Y., Yang, R., Chen, Z., Hu, W., Wu, Y., Gao, M., Xu, X., Qin, Y., et al. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.12.006 · Cited by 97 · see citing works
Karbownik, M. S., Sokołowska, P., & Kowalczyk, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076617 · Cited by 6 · see citing works
- Authors
- Resende, W. R., Valvassori, S. S., Réus, G. Z., Varela, R. B., Arent, C. O., Ribeiro, K. F., Bavaresco, D. V., Andersen, M. L., Zugno, A. I., & Quevedo, J.
- Affiliations
- Universidade do Sul de Santa Catarina (BR)
- Corresponding author
- Valvassori, Samira S.
- ORCID
- Venue
- Behavioural Pharmacology
- Published
- 2013-10
- Volume
- 24
- Issue
- 7
- Pages
- 569-579
- ISSN
- 0955-8810 (ISSN-L)
- OpenAlex
- W2086852082
- Cited by
- 65
- References
- 8
- Citations by year
- 2026: 2 · 2025: 13 · 2024: 1 · 2023: 7 · 2022: 8 · 2021: 5 · 2020: 7 · 2019: 5 · 2018: 1 · 2017: 5 · 2016: 2 · 2015: 3 · 2014: 6
- FWCI
- 2.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Behavioural Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Funders
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- sodium butyrate, bipolar disorder, mania, depression, histone deacetylase inhibitors, mood stabilizers, chronic mild stress, maternal deprivation, depression-like behavior, manic-like behavior
- MeSH terms
- Affect, Animals, Behavior, Animal, Bipolar Disorder, Disease Models, Animal, Male, Rats, Wistar, Antimanic Agents, Butyric Acid, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
